• 1
    The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:913.
  • 2
    Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:20017.
  • 3
    Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol hear failure study group. N Engl J Med. 1996;334:134955.
  • 4
    Ansari M, Alexander M, Tutar A, Bello D, Massie BM. Cardiology participation improves outcomes in patients with new-onset heart failure in the outpatient setting. J Am Coll Cardiol. 2003;41:628.
  • 5
    Gupta R, Tang WH, Young JB. Patterns of beta-blocker utilization in patients with chronic heart failure: experience from a specialized outpatient heart failure clinic. Am Heart J. 2004;147:7983.
  • 6
    Hulsmann M, Berger R, Mortl D, Pacher R. Influence of age and in-patient care on prescription rate and long-term outcome in chronic heart failure: a data-based substudy of the euroheart failure survey. Eur J Heart Failure. 2005;7:65761.
  • 7
    Maggioni AP, Sinagra G, Opasich C, et al. Treatment of chronic heart failure with beta adrenergic blockade beyond controlled clinical trials: the BRING-UP experience. Heart. 2003;89:299305.
  • 8
    Ross J Jr., Braunwald E. Studies on starling's law of the heart. Ix. the effects of impeding venous return on performance of the normal and failing human left ventricle. Circulation. 1964;30:71927.
  • 9
    Rutten FH, Grobbee DE, Hoes AW. Differences between general practitioners and cardiologists in diagnosis and management of heart failure: a survey in every-day practice. Eur J Heart Failure. 2003;5:33744.
  • 10
    Kimmelstiel C, Levine D, Perry K, et al. Randomized, controlled evaluation of short- and long-term benefits of heart failure disease management within a diverse provider network: the SPAN-CHF trial. Circulation. 2004;110:14505.
  • 11
    Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest. 2005;128:26406.
  • 12
    Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med. 2002;137:71525.
  • 13
    Bobbio M, Ferrua S, Opasich C, et al. Survival and hospitalization in heart failure patients with or without diabetes treated with beta-blockers. J Cardiac Failure. 2003;9:192202.
  • 14
    Fleiss J. Statistical Methods for Rates and Proportions. 2nd edn. New York: Wiley; 1981.
  • 15
    Patel JA, Fotis MA. Comparison of treatment of patients with congestive heart failure by cardiologists versus noncardiologists. Am J Health Syst Pharm. 2005;62:16872.
  • 16
    Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998;339:48997.
  • 17
    Solomon SD, Anavekar N, Skali H, et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation. 2005;112:373844.
  • 18
    Lee DS, Mamdani MM, Austin PC, et al. Trends in heart failure outcomes and pharmacotherapy: 1992 to 2000. Am J Med. 2004;116:5819.
  • 19
    Kotlyar E, Keogh AM, Macdonald PS, Arnold RH, McCaffrey DJ, Glanville AR. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. J Heart Lung Transplant. 2002;21:12905.
  • 20
    Krum H, Hill J, Fruhwald F, et al. Tolerability of beta-blockers in elderly patients with chronic heart failure: the COLA II study. Eur J Heart Fail. 2006;8:3027.
  • 21
    Asch SM, McGlynn EA, Hogan MM, et al. Comparison of quality of care for patients in the Veterans health administration and patients in a national sample. Ann Intern Med. 2004;141:93845.